Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,025,404
  • Shares Outstanding, K 37,782
  • Annual Sales, $ 17,450 K
  • Annual Income, $ -135,890 K
  • 60-Month Beta 1.06
  • Price/Sales 58.56
  • Price/Cash Flow N/A
  • Price/Book 3.74
Trade TARS with:

Options Overview Details

View History
  • Implied Volatility 90.15% ( -1.64%)
  • Historical Volatility 53.73%
  • IV Percentile 62%
  • IV Rank 50.00%
  • IV High 144.49% on 09/14/23
  • IV Low 35.79% on 10/31/23
  • Put/Call Vol Ratio 0.05
  • Today's Volume 44
  • Volume Avg (30-Day) 296
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 6,899
  • Open Int (30-Day) 11,942

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.98
  • Number of Estimates 6
  • High Estimate -0.83
  • Low Estimate -1.10
  • Prior Year -1.17
  • Growth Rate Est. (year over year) +16.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.42 +11.26%
on 06/27/24
31.30 -13.19%
on 07/12/24
+1.09 (+4.18%)
since 06/21/24
3-Month
24.42 +11.26%
on 06/27/24
42.50 -36.07%
on 05/09/24
-6.54 (-19.40%)
since 04/23/24
52-Week
12.57 +116.15%
on 10/17/23
42.50 -36.07%
on 05/09/24
+2.55 (+10.36%)
since 07/21/23

Most Recent Stories

More News
2 Under the Radar Small-Cap Stocks Wall Street Analysts Think Will Double

As small-cap stocks gain traction amid a broader market rotation out of Big Tech stocks, here are two market underdogs poised for explosive growth, according to analysts.

TARS : 27.20 (+0.22%)
LUNR : 4.27 (+1.43%)
$SPX : 5,572.48 (+0.15%)
Why Shares of Tarsus Pharmaceuticals Are Up Thursday

The company's lead therapy is getting close to the finish line of FDA approval.

TARS : 27.20 (+0.22%)
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease

IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...

TARS : 27.20 (+0.22%)
Tarsus to Present at the Jefferies 2022 Healthcare Conference

IRVINE, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...

TARS : 27.20 (+0.22%)
Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements

TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year ...

TARS : 27.20 (+0.22%)
Tarsus to Present at Bank of America 2022 Healthcare Conference

IRVINE, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...

TARS : 27.20 (+0.22%)
Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock

IRVINE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the “Company” or “Tarsus”), whose mission is to focus on...

TARS : 27.20 (+0.22%)
Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock

IRVINE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the “Company” or “Tarsus”), whose mission is to focus on...

TARS : 27.20 (+0.22%)
Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year

TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related...

TARS : 27.20 (+0.22%)
Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...

TARS : 27.20 (+0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based...

See More

Key Turning Points

3rd Resistance Point 29.40
2nd Resistance Point 28.66
1st Resistance Point 27.90
Last Price 27.30
1st Support Level 26.40
2nd Support Level 25.66
3rd Support Level 24.90

See More

52-Week High 42.50
Fibonacci 61.8% 31.07
Fibonacci 50% 27.53
Last Price 27.30
Fibonacci 38.2% 24.00
52-Week Low 12.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar